CAPTRUST Financial Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-5,234
| Closed | -$690K | – | 2608 |
|
|
2025
Q1 | $690K | Sell |
5,234
-4,422
| -46% | -$551K | ﹤0.01% | 1467 |
|
|
2024
Q4 | $806K | Buy |
9,656
+1,606
| +20% | +$132K | ﹤0.01% | 1350 |
|
|
2024
Q3 | $589K | Buy |
8,050
+2,572
| +47% | +$193K | ﹤0.01% | 1484 |
|
|
2024
Q2 | $375K | Sell |
5,478
-1,239
| -18% | -$85.9K | ﹤0.01% | 1670 |
|
|
2024
Q1 | $465K | Sell |
6,717
-13,210
| -66% | -$908K | ﹤0.01% | 1522 |
|
|
2023
Q4 | $1.43M | Sell |
19,927
-6,795
| -25% | -$391K | ﹤0.01% | 1069 |
|
|
2023
Q3 | $1.39M | Buy |
26,722
+7,942
| +42% | +$463K | 0.01% | 1010 |
|
|
2023
Q2 | $1.19M | Buy |
18,780
+13,075
| +229% | +$815K | ﹤0.01% | 1106 |
|
|
2023
Q1 | $309K | Sell |
5,705
-53
| -0.9% | -$2.56K | ﹤0.01% | 1725 |
|
|
2022
Q4 | $305K | Buy |
+5,758
| New | +$289K | ﹤0.01% | 1642 |
|
|
2022
Q3 | – | Sell |
-984
| Closed | -$56K | – | 4193 |
|
|
2022
Q2 | $56K | Sell |
984
-21
| -2% | -$1.19K | ﹤0.01% | 2660 |
|
|
2022
Q1 | $61K | Buy |
1,005
+99
| +11% | +$5.14K | ﹤0.01% | 2654 |
|
|
2021
Q4 | $47K | Buy |
906
+231
| +34% | +$9.7K | ﹤0.01% | 2727 |
|
|
2021
Q3 | $25K | Buy |
675
+90
| +15% | +$3.13K | ﹤0.01% | 3024 |
|
|
2021
Q2 | $24K | Hold |
585
| – | – | ﹤0.01% | 2985 |
|
|
2021
Q1 | $20K | Buy |
585
+285
| +95% | +$9.89K | ﹤0.01% | 3010 |
|
|
2020
Q4 | $10K | Hold |
300
| – | – | ﹤0.01% | 2580 |
|
|
2020
Q3 | $8K | Hold |
300
| – | – | ﹤0.01% | 2385 |
|
|
2020
Q2 | $8K | Buy |
+300
| New | +$6.07K | ﹤0.01% | 2277 |
|
Other funds holding ITCI
CAPTRUST Financial Advisors's ITCI Position: Q2 2025 in Review
CAPTRUST Financial Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 5,234 shares — an estimated $690K sold.
CAPTRUST Financial Advisors first reported a position in ITCI in Q2 2020 and held it in 19 quarters. The position peaked at $1.43M in Q4 2023. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.
- CAPTRUST Financial Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
- CAPTRUST Financial Advisors sold 5,234 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $690K.
- CAPTRUST Financial Advisors first reported a position in Intra-Cellular Therapies Inc. in Q2 2020 and held it in 19 quarters.
- CAPTRUST Financial Advisors's Intra-Cellular Therapies Inc. position peaked at $1.43M in Q4 2023.
- 3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.
Based on CAPTRUST Financial Advisors's 13F filing for Q2 2025, filed 15 Aug 2025.